IL154404A0 - Oral solid dose vaccine - Google Patents

Oral solid dose vaccine

Info

Publication number
IL154404A0
IL154404A0 IL15440401A IL15440401A IL154404A0 IL 154404 A0 IL154404 A0 IL 154404A0 IL 15440401 A IL15440401 A IL 15440401A IL 15440401 A IL15440401 A IL 15440401A IL 154404 A0 IL154404 A0 IL 154404A0
Authority
IL
Israel
Prior art keywords
oral solid
solid dose
dose vaccine
vaccine
oral
Prior art date
Application number
IL15440401A
Other languages
English (en)
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of IL154404A0 publication Critical patent/IL154404A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
IL15440401A 2000-08-15 2001-08-14 Oral solid dose vaccine IL154404A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0020089.9A GB0020089D0 (en) 2000-08-15 2000-08-15 Vaccine Composition
PCT/IB2001/001711 WO2002013858A1 (en) 2000-08-15 2001-08-14 Oral solid dose vaccine

Publications (1)

Publication Number Publication Date
IL154404A0 true IL154404A0 (en) 2003-09-17

Family

ID=9897656

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15440401A IL154404A0 (en) 2000-08-15 2001-08-14 Oral solid dose vaccine

Country Status (17)

Country Link
US (1) US20040013695A1 (zh)
EP (1) EP1309344A1 (zh)
JP (1) JP2004506020A (zh)
KR (1) KR20030031978A (zh)
CN (1) CN1842345A (zh)
AU (2) AU2001286168B2 (zh)
BR (1) BR0113301A (zh)
CA (1) CA2424160A1 (zh)
GB (1) GB0020089D0 (zh)
HU (1) HUP0301697A3 (zh)
IL (1) IL154404A0 (zh)
MX (1) MXPA03001392A (zh)
NO (1) NO20030713L (zh)
NZ (1) NZ524164A (zh)
PL (1) PL362481A1 (zh)
WO (1) WO2002013858A1 (zh)
ZA (1) ZA200301210B (zh)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000891D0 (en) * 2000-01-14 2000-03-08 Allergy Therapeutics Ltd Formulation
US20040247565A1 (en) * 2000-07-19 2004-12-09 Chih-Ping Liu Method of treatment using interferon-tau
US20050226845A1 (en) * 2004-03-10 2005-10-13 Chih-Ping Liu Method of treatment using interferon-tau
US20050201981A1 (en) * 2004-03-10 2005-09-15 Chih-Ping Liu Method of optimizing treatment with interferon-tau
US7431920B2 (en) * 2000-07-19 2008-10-07 Pepgen Corporation Method of treating IL-10 deficiency
US20050084478A1 (en) * 2000-10-17 2005-04-21 Chih-Ping Liu Combination therapy using interferon-tau
US20050118138A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US20050118137A1 (en) * 2000-07-19 2005-06-02 Chih-Ping Liu Method of treatment using interferon-tau
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
DK2116257T3 (da) 2000-08-09 2013-02-04 Alk Abello As Parenterale vaccineformuleringer og anvendelser deraf
WO2003059380A2 (de) * 2002-01-15 2003-07-24 Bio Life Science Forschungs Und Entwicklungsges M.B.H. Orale vakzinierung
DE10224086A1 (de) 2002-05-31 2003-12-11 Bayer Ag Pharmazeutische Zubereitungen zur oralen Anwendung enthaltend wirkstoffbeladene Ionentauscherharze sowie strukturviskose Gelbildner als Verdicker
WO2004047793A1 (en) 2002-11-26 2004-06-10 Alk-Abelló A/S Pharmaceutical allergen product
WO2004075875A1 (en) 2003-02-28 2004-09-10 Alk-Abello A/S Dosage form having a saccharide matrix
US8012505B2 (en) 2003-02-28 2011-09-06 Alk-Abello A/S Dosage form having a saccharide matrix
US9050352B2 (en) 2003-10-16 2015-06-09 Stephen John Ralph Immunomodulating compositions and uses therefor
US20080025948A1 (en) * 2004-03-10 2008-01-31 Chih-Ping Liu Methods of Treatment Using Interferon-Tau
US20060078942A1 (en) * 2004-03-10 2006-04-13 Pepgen Corporation Method of treatment using interferon-tau
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
JP2009510136A (ja) 2005-10-04 2009-03-12 アルク−アベッロ エイ／エス 固体ワクチン製剤
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
ATE542540T1 (de) 2007-09-11 2012-02-15 Uinv Kobenhavns Vorbeugung von diabetes durch verabreichung von gliadin
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
FR2960781B1 (fr) * 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
KR101751964B1 (ko) 2010-10-08 2017-06-28 알.피.쉐러 테크놀러지즈 엘엘씨 전분을 이용한 경구 백신 급속 용해성 투여 형태
JP6034798B2 (ja) 2010-12-02 2016-11-30 オンコリティクス バイオテク，インコーポレーテッド 液体ウイルス製剤
TW201233803A (en) 2010-12-02 2012-08-16 Oncolytics Biotech Inc Lyophilized viral formulations
WO2012103464A2 (en) * 2011-01-28 2012-08-02 Brian Pulliam Oral thin film vaccine preparation
JP6253161B2 (ja) * 2012-03-05 2017-12-27 デ スタート デル ネーデルランデン， ヴェルト． ドール デ ミニステル ヴァン ヴイダブリューエス ミニステリー ヴァン ボルクスゲツォントヘイト， ベルジーン エン シュポルトＤｅ Ｓｔａａｔ Ｄｅｒ Ｎｅｄｅｒｌａｎｄｅｎ， Ｖｅｒｔ． Ｄｏｏｒ Ｄｅ Ｍｉｎｉｓｔｅｒ Ｖａｎ Ｖｗｓ Ｍｉｎｉｓｔｅｒｉｅ Ｖａｎ Ｖｏｌｋｓｇｅｚｏｎｄｈｅｉｄ， Ｗｅｌｚｉｊｎ Ｅｎ Ｓｐｏｒｔ 乾燥された生物学的材料を安定化するための方法及び組成物
WO2015013549A1 (en) * 2013-07-25 2015-01-29 Invado Pharmaceuticals, LLC Treating oral inflammation, injury or pain
KR102411781B1 (ko) * 2013-12-31 2022-06-22 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) 단일 바이알 백신 제형
EP2952200A1 (en) 2014-06-04 2015-12-09 Alk-Abelló A/S Allergen for prophylactic treatment of allergy
WO2017090766A1 (ja) 2015-11-27 2017-06-01 日東電工株式会社 口腔内投与用ワクチン医薬組成物及び口腔内投与用ワクチン医薬組成物の製造方法
TW201720426A (zh) 2015-11-27 2017-06-16 Nitto Denko Corp 流感疫苗乾燥製劑、及流感疫苗乾燥製劑之製造方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4636385A (en) * 1985-02-15 1987-01-13 The Wistar Institute Of Anatomy & Biology Vaccine, method for its preparation, and use thereof in vaccinating humans against rotavirus infection
GB9722682D0 (en) * 1997-10-27 1997-12-24 Scherer Ltd R P Pharmaceutical products
HU228975B1 (en) * 1999-08-17 2013-07-29 Smithkline Beecham Biolog Vaccine
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신

Also Published As

Publication number Publication date
CA2424160A1 (en) 2002-02-21
EP1309344A1 (en) 2003-05-14
GB0020089D0 (en) 2000-10-04
HUP0301697A2 (hu) 2003-08-28
NO20030713D0 (no) 2003-02-14
US20040013695A1 (en) 2004-01-22
BR0113301A (pt) 2003-07-15
KR20030031978A (ko) 2003-04-23
WO2002013858A1 (en) 2002-02-21
PL362481A1 (en) 2004-11-02
NO20030713L (no) 2003-04-11
JP2004506020A (ja) 2004-02-26
CN1842345A (zh) 2006-10-04
AU8616801A (en) 2002-02-25
NZ524164A (en) 2004-10-29
ZA200301210B (en) 2004-03-12
HUP0301697A3 (en) 2004-11-29
AU2001286168B2 (en) 2004-09-23
MXPA03001392A (es) 2004-12-13

Similar Documents

Publication Publication Date Title
HUP0301697A3 (en) Oral solid dose vaccine
ZA200003121B (en) Flash-melt oral dose formulations.
HUP0203204A3 (en) Oral dosage forms
GB0020953D0 (en) Vaccine
HUP0301043A3 (en) Vaccine
IL155072A0 (en) Vaccine
AP2002002700A0 (en) Vaccine composition
AU1591402A (en) Vaccine
GB0014288D0 (en) Vaccine
HUP0401599A3 (en) Extended release oral dosage form
EP1429615A4 (en) ORAL VACCINES
EP1357898A4 (en) ORAL DOSAGE FORM WITH ENHANCED REGULATED RELEASE
GB0026334D0 (en) Vaccine
GB0014845D0 (en) Vaccine
GB0025694D0 (en) Vaccine
GB0003082D0 (en) Vaccine
GB9911823D0 (en) New vaccine formulations
GB0006693D0 (en) Vaccine
GB0015722D0 (en) Vaccine
GB0014497D0 (en) Oral dosage form
HK1047232A1 (zh) 口服劑型
GB0015935D0 (en) Vaccine
GB0008029D0 (en) New vaccine formulations
GB9925069D0 (en) Oral dosage form
PL341178A1 (en) Oral pharmaceutical dosage forms